Nektar Therapeutics

LSE:0UNL Stock Report

Market Cap: US$193.7m

Nektar Therapeutics Valuation

Is 0UNL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0UNL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0UNL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0UNL's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0UNL?

Key metric: As 0UNL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0UNL. This is calculated by dividing 0UNL's market cap by their current revenue.
What is 0UNL's PS Ratio?
PS Ratio2.1x
SalesUS$93.14m
Market CapUS$193.68m

Price to Sales Ratio vs Peers

How does 0UNL's PS Ratio compare to its peers?

The above table shows the PS ratio for 0UNL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2x
ANCR Animalcare Group
2x3.8%UK£148.5m
APH Alliance Pharma
1.3x5.2%UK£245.1m
AGY Allergy Therapeutics
4.3x19.2%UK£238.8m
EAH ECO Animal Health Group
0.5x5.9%UK£43.4m
0UNL Nektar Therapeutics
2.1x11.8%US$193.7m

Price-To-Sales vs Peers: 0UNL is expensive based on its Price-To-Sales Ratio (2.1x) compared to the peer average (2x).

Price to Sales Ratio vs Industry

How does 0UNL's PS Ratio compare vs other companies in the GB Pharmaceuticals Industry?

1 CompanyPrice / SalesEstimated GrowthMarket Cap
EAH ECO Animal Health Group
0.5x5.9%US$54.43m
No more companies available in this PS range
0UNL 2.1xIndustry Avg. 2.9xNo. of Companies6PS048121620+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0UNL is good value based on its Price-To-Sales Ratio (2.1x) compared to the European Pharmaceuticals industry average (2.9x).

Price to Sales Ratio vs Fair Ratio

What is 0UNL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0UNL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.1x
Fair PS Ratio2.6x

Price-To-Sales vs Fair Ratio: 0UNL is good value based on its Price-To-Sales Ratio (2.1x) compared to the estimated Fair Price-To-Sales Ratio (2.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0UNL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.11
US$4.10
+269.2%
56.8%US$7.00US$1.30n/a3
Nov ’25US$1.25
US$2.65
+112.0%
50.9%US$4.00US$1.30n/a2
Oct ’25US$1.29
US$2.65
+105.3%
50.9%US$4.00US$1.30n/a2
Feb ’25US$0.52
US$2.75
+425.8%
81.8%US$5.00US$0.50n/a2
Jan ’25US$0.56
US$2.75
+388.0%
81.8%US$5.00US$0.50n/a2
Dec ’24US$0.50
US$2.75
+452.8%
81.8%US$5.00US$0.50n/a2
Nov ’24US$0.48
US$2.88
+501.1%
67.8%US$6.00US$1.00US$1.254
Oct ’24US$0.60
US$2.88
+375.3%
67.8%US$6.00US$1.00US$1.294
Sep ’24US$0.60
US$2.35
+291.1%
76.7%US$6.00US$0.60US$1.266
Aug ’24US$0.52
US$2.35
+353.6%
76.7%US$6.00US$0.60US$1.256
Jul ’24US$0.58
US$2.38
+310.5%
74.9%US$6.00US$0.75US$1.146
Jun ’24US$0.60
US$2.55
+323.0%
74.5%US$6.00US$0.75US$1.245
May ’24US$0.80
US$2.54
+218.6%
63.3%US$6.00US$0.75US$1.557
Apr ’24US$0.69
US$2.93
+324.5%
46.9%US$6.00US$1.50US$0.917
Mar ’24US$1.45
US$3.46
+138.4%
47.2%US$6.00US$1.50US$0.777
Feb ’24US$2.81
US$4.41
+57.2%
22.5%US$6.00US$3.00US$0.527
Jan ’24US$2.21
US$4.41
+99.7%
22.5%US$6.00US$3.00US$0.567
Dec ’23US$2.80
US$4.53
+61.7%
19.6%US$6.00US$3.00US$0.507
Nov ’23US$3.82
US$4.53
+18.5%
19.6%US$6.00US$3.00US$0.487

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Formycon

€848.4m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.50

7D

4.3%

1Y

-21.3%

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€63.05

7D

1.3%

1Y

13.6%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$745.13

7D

-2.1%

1Y

-6.5%